|
PPP2R3C expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.81989995190679E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.22199999697781E-08 |
| Normal-vs-Stage2 |
2.008200E-04 |
| Normal-vs-Stage3 |
2.3569999996198E-07 |
| Normal-vs-Stage4 |
2.16299977928713E-10 |
| Stage1-vs-Stage2 |
7.780800E-01 |
| Stage1-vs-Stage3 |
4.293800E-01 |
| Stage1-vs-Stage4 |
2.476500E-03 |
| Stage2-vs-Stage3 |
4.455400E-01 |
| Stage2-vs-Stage4 |
1.094450E-02 |
| Stage3-vs-Stage4 |
3.221600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.66269994941837E-09 |
| Normal-vs-AfricanAmerican |
6.843800E-03 |
| Normal-vs-Asian |
1.379060E-04 |
| Caucasian-vs-AfricanAmerican |
2.857600E-01 |
| Caucasian-vs-Asian |
4.464200E-01 |
| AfricanAmerican-vs-Asian |
6.762600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.41769999961738E-07 |
| Normal-vs-Female |
8.81210004965993E-09 |
| Male-vs-Female |
7.995600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.99499999975883E-07 |
| Normal-vs-Age(41-60Yrs) |
1.48760004314852E-09 |
| Normal-vs-Age(61-80Yrs) |
3.32140000003367E-06 |
| Normal-vs-Age(81-100Yrs) |
2.599700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.461810E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.527800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.626200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.755000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.780000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.450000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.154440E-02 |
| Classical-VS-Follicular |
3.382400E-01 |
| Classical-VS-Other |
3.228200E-01 |
| Classical-VS-Normal |
4.49920001255322E-09 |
| Tall-VS-Follicular |
4.255300E-03 |
| Tall-VS-Other |
7.711600E-01 |
| Tall-VS-Normal |
5.10739994741272E-09 |
| Follicular-VS-Other |
2.828200E-01 |
| Follicular-VS-Normal |
3.191900E-04 |
| Other-VS-Normal |
2.002400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.39579999949946E-07 |
| Normal-vs-N1 |
1.40339961873792E-11 |
| N0-vs-N1 |
1.103940E-03 |
|
|
